Rubius Therapeutics’ $200 Million Underwritten Public Offering

Martina Bellini
Tagged:

Goodwin Procter LLP advised Rubius Therapeutics on the deal.Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at a…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

…

This content is for Standard 1 Year members only.
Login Join Now